A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q

(2017) K. T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience

(2017) A. Elfiky et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422

(2017) J. C. Bryson et al.   JOURNAL OF CLINICAL ONCOLOGY

The Hsp90 molecular chaperone: an open and shut case for treatment

(2008) Laurence H. Pearl et al.   BIOCHEMICAL JOURNAL

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

(2008) D. B. Solit et al.   CLINICAL CANCER RESEARCH

Targeting Hsp90: small-molecule inhibitors and their clinical development

(2008) Tony Taldone et al.   CURRENT OPINION IN PHARMACOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY